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Abstract
 Background—BRCA1 interacting protein C-terminal helicase 1 (BRIP1) is one of the 
Fanconi Anaemia Complementation (FANC) group family of DNA repair proteins. Biallelic 
mutations in BRIP1 are responsible for FANC group J, and previous studies have also suggested 
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that rare protein truncating variants in BRIP1 are associated with an increased risk of breast 
cancer. These studies have led to inclusion of BRIP1 on targeted sequencing panels for breast 
cancer risk prediction.
 Methods—We evaluated a truncating variant, p.Arg798Ter (rs137852986), and 10 missense 
variants of BRIP1, in 48 144 cases and 43 607 controls of European origin, drawn from 41 studies 
participating in the Breast Cancer Association Consortium (BCAC). Additionally, we sequenced 
the coding regions of BRIP1 in 13 213 cases and 5242 controls from the UK, 1313 cases and 1123 
controls from three population-based studies as part of the Breast Cancer Family Registry, and 
1853 familial cases and 2001 controls from Australia.
 Results—The rare truncating allele of rs137852986 was observed in 23 cases and 18 controls 
in Europeans in BCAC (OR 1.09, 95% CI 0.58 to 2.03, p=0.79). Truncating variants were found in 
the sequencing studies in 34 cases (0.21%) and 19 controls (0.23%) (combined OR 0.90, 95% CI 
0.48 to 1.70, p=0.75).
 Conclusions—These results suggest that truncating variants in BRIP1, and in particular 
p.Arg798Ter, are not associated with a substantial increase in breast cancer risk. Such observations 
have important implications for the reporting of results from breast cancer screening panels.
 INTRODUCTION
Susceptibility to breast cancer is known to be mediated through a very large number of 
genetic variants conferring a wide range of disease risks relative to population incidence 
rates.1 These variants include rare mutations in high-penetrance genes (fourfold or higher 
risk), notably BRCA1 and BRCA2, mutations in genes conferring more moderate risks of 
breast cancer (twofold to fourfold higher risks), and approximately 100 common 
susceptibility variants (SNPs) conferring modest risks of the disease (typically 1.1–1.2-fold). 
Clinical genetic testing for breast cancer has largely focused on the high-risk genes. 
However, with the increasing use of high-throughput sequencing, genetic testing is being 
extended to larger panels of genes, including those in the ‘moderate-risk’ category.2
The known genes in the moderate-risk category encode proteins involved in DNA repair. 
One of the genes involved in DNA repair that has been proposed as a breast cancer 
susceptibility gene is BRIP1. BRIP1 (BRCA1-interacting protein 1, also known as BACH1) 
encodes a helicase-like protein that was identified via its direct binding to the BRCA1 
BRCT domains, and is known to contribute to DNA repair via homologous recombination.34 
BRIP1 was shown to be the likely causative gene for Fanconi Anaemia Complementation 
group J through positional cloning and the identification of germline mutations in nine 
families from two studies.45 The most common truncating mutation identified was c.
2392C>T (p.Arg798Ter) in exon 17. Analysis of a cell line from a patient homozygous for 
this mutation showed complete absence of the full-length BRIP1 protein.4 p.Arg798Ter has 
been found in patients from diverse populations, suggesting that it is either a relatively 
ancient founder mutation or is recurrent.
Given the role of BRCA1 and other genes involved in DNA repair in susceptibility to breast 
and other cancers, it seems reasonable to speculate that germline mutations of BRIP1 might 
also predispose to breast cancer. Seal et al6 screened the coding sequence of 1212 women 
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with breast cancer having a family history of disease and 2012 controls. They identified 
mutations predicted to lead to a truncated protein in nine cases versus two in controls and 
obtained an estimated relative risk of breast cancer, after adjustment for oversampling of 
cases with a family history, of 2.0 (95% CI 1.2 to 3.2, p=0.012). The most common mutation 
was p. Arg798Ter, accounting for five of the mutations in cases and one in controls.
Since the Seal et al6 paper, several other studies have identified BRIP1 variants through 
screening of breast cancer cases for specific mutations,7–12 but no large-scale case–control 
mutation screening studies have been reported. To evaluate more definitively the evidence 
that BRIP1 is a breast cancer susceptibility gene, we genotyped the p.Arg798Ter variant and 
10 missense variants in >48 000 cases and 43 000 controls in studies participating in the 
Breast Cancer Association Consortium (BCAC). Additionally, we screened the entire coding 
sequence of BRIP1 in three large case–control studies comprising >16 000 cases and 8000 
controls.
 METHODS
 Breast Cancer Association Consortium
Breast cancer cases and controls were drawn from 52 studies participating in the BCAC. The 
analysis was restricted to 48 143 cases and 43 608 controls from 41 studies in populations of 
European origin (comprising ~87% of the data set) since the sample sizes for Asian and 
African-American women were too small for separate analysis. The truncating variant 
p.Arg798Ter and 10 missense variants in BRIP1 (table 1) were genotyped using iCOGS, a 
custom array of ~200 000 variants.13 Genotypes were subject to standard quality control 
procedures as described previously.13
For the purpose of this analysis, we manually recalled the genotypes for BRIP1 p.Arg798Ter 
using the cluster plot of normalised intensities (figure 1). The experiment included a positive 
control previously identified as a carrier of the mutant allele through sequencing of a series 
of prostate cancer cases. This individual was genotyped correctly as a variant carrier. We 
further confirmed the genotypes through comparison with data from two re-sequencing 
experiments conducted in Studies of Epidemiology and Risk Factors in Cancer Heredity 
(SEARCH) and the Breast Cancer Family Registry (BCFR), for which individuals were also 
genotyped using iCOGS (see below). Thirteen individuals in the former study and two in the 
latter study were identified as carrying the variant allele at p.Arg798Ter; genotypes 
determined by the two methods were 100% concordant.
 SEARCH study
 Subjects—Cases were drawn from SEARCH, a population-based study of breast cancer 
in the region covered by the Eastern Cancer Registration and Information Centre, UK.14 
SEARCH recruited patients diagnosed with invasive breast cancer before the age of 55 years 
since 1991 and still alive at the start of the study in 1996 (prevalent cases; median age 48 
years), together with all those diagnosed before 70 years of age between 1996 and 2014. The 
study was approved by the Cambridgeshire Research Ethics Committee. The present 
analysis is based on data from 13 824 case participants. Controls were drawn from the 
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EPIC-Norfolk study, a population-based cohort study of diet and health women attending 
general practitioner (GP) practices, frequency matched to cases by age and geographic 
region (2003–present),14 and women attending breast screening as part of the National 
Health Service Breast Screening Program participating in the Sisters in Breast Screening 
study.15 The final analyses were based on 13 213 cases and 5242 controls that passed QC 
filters (see below).
 Mutation screening—Target enrichment was accomplished using the 48.48 Fluidigm 
Access Array system. This approach employed multiplexed microfluidic PCR reactions to 
first amplify targeted regions and then ligate one of 1536 unique barcodes and sequencing 
adapters. To cover the 19 protein-coding exons and associated splice junctions of BRIP1, we 
designed 45 PCR amplicons that were 133–199 bp in length, which together produced 
unique coverage of 3750 bp, as part of a larger multiplex panel involving ~500 amplicons. 
The amplicon designs covered 100% of the targeted regions. Fourteen 1536-sample 
sequencing libraries were produced according to the manufacturer’s protocol (Fluidigm, San 
Francisco, California, USA) and assayed with the KAPA library quantification kit with 
specific probes for the ends of the adapters (KapaBiosystems, Boston, Massachusetts, USA). 
Libraries were sequenced in paired end mode on the Illumina HiSeq 2000 and CASAVA was 
used to construct demultiplexed sequence files, according to the manufacturer’s protocols 
(Illumina, San Diego, California, USA). Cutadapt V.1.5 was used to remove primer 
sequences from both ends of each read, and untrimmed reads were discarded.16 Reads were 
aligned to the hg19 human genome reference sequence using BWA-MEM V.0.7,17 and 
GATK V.3.3-0-g37228af was used for base quality score recalibration and indel realignment, 
and for deriving quality and depth metrics.18 BRIP1 was segmented into intervals of 2–7 
exons, and the GATK UnifiedGenotyper was used to perform SNP and indel discovery and 
genotyping across all samples simultaneously, according to GATK Best Practices 
recommendations.19 The samples had a median coverage of 446.4, and a median of 97.47% 
of the targeted region (coding exons with 6 bp of flanking sequence) covered in each sample. 
In initial filtering, variants with >20% missing data were removed, and samples with no 
genotype at >20% of remaining positions were also excluded. Genotypes with depth <20 or 
genotype quality <13 were re-coded as no genotype. GATK was used to recalculate variant-
level metrics without these failed samples and low-confidence genotypes, and positions 
genotyped in >95% of samples and with quality by depth between 3.0 and 25.0 were 
retained for further analysis. The remaining variants were annotated with Combined 
Annotation-Dependent Depletion (CADD) V.1.2,20 and 40 truncating and predicted 
damaging missense variants were selected for Sanger sequencing. Of these, 39 (positive 
predictive value 97.5%) variants were successfully confirmed.
iCOGS data were available for 13 133 individuals that were also sequenced. Six rare coding 
variants (MAF<1%) were polymorphic in the iCOGS data. Of the 357 rare allele carriers 
identified by iCOGS, the sequencing identified 355 (99.4%), although for two of the variants 
(p.Val193Ile and p.Arg173Ser), 13/111 and 17/138 of individuals called heterozygotes by 
iCOGS genotyping were called rare allele homozygotes by sequencing, reflecting bias in 
PCR amplification. One common coding polymorphism (rs4986764, p.Ser919Pro) was 
concordant in 99.9% of samples.
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 BCFR study
 Subjects—Eligible participants included women ascertained by population-based 
sampling by the Australian, Northern Californian and Ontarian sites of the BCFR between 
1995 and 2005.21 For the present study, the selection criteria for cases (n=1313) were 
diagnosis of breast cancer at <45 years of age and self-reported race/ethnicity, plus 
grandparents’ country of origin information consistent with Caucasian, East Asian, 
Hispanic/Latino, or African-American racial/ethnic heritage. The controls (n=1123) were 
frequency-matched to the cases within each centre by racial/ethnic group, with age at 
selection not more than 10 years older or younger than the age at diagnosis of the cases 
ascertained at the same centre. The design of this study has been described in detail 
previously.22–27 Recruitment and genetic studies were approved by the Ethics Committee of 
the International Agency for Research on Cancer (Lyon, France), the University of Utah 
Institutional Review Boards (IRBs) and the local IRBs of the BCFR centres from which 
samples were received. Written informed consent was obtained from each participant.
 Mutation screening—Mutation screening was carried out using 30 ng of whole-
genome amplified (WGA) DNA and covered the 19 coding exons of BRIP1 
(NM_032043.2). The laboratory process has been described in detail for our recent studies 
of ATM,22 CHEK2,23 XRCC2,24RAD51,25 RINT126 and MRN genes.27 The semi-
automated approach relies on mutation scanning by high-resolution melt curve (HRM) 
analysis followed by direct Sanger sequencing of the individual samples for which an 
aberrant melt curve profile is indicative of the presence of a sequence variant. In our 
previous work, we showed, by comparing the results with those obtained with Sanger 
sequencing,28 that the HRM technique showed high sensitivity and specificity (1.0 and 0.8, 
respectively, for amplicons of <400 bp) for mutation screening. All rare exonic variants, plus 
intronic variants that fell within 20 bp of a splice acceptor site or 8 bp of a splice donor site, 
were independently re-amplified from the two WGA reaction products to confirm the 
presence of the variant using direct Sanger sequencing. Primer and HRM probe sequences 
are available from the authors upon request.
 Peter MacCallum Cancer Centre study
 Subjects—The familial cohort included 1853 index individuals with personal and family 
histories of breast cancer who were previously assessed at Familial Cancer Centres in 
Victoria and New South Wales. A total of 979 cases were obtained from the ‘Variants in 
Practice’ study, which recruited via the combined Familial Cancer Centers in Melbourne, 
Australia,29 and 874 through the Hunter Area Pathology Service, Newcastle, Australia. All 
index cases were previously screened through their clinical genetics services and found to be 
negative for mutations in BRCA1 and BRCA2. Large deletions and duplications in BRCA1 
and BRCA2 were included in the mutational analysis as determined by multiplex ligation-
dependent probe amplification analysis. The 2001 female controls were accessed through 
Lifepool (http://www.lifepool.org), which is a cohort of women attending population 
mammography screening programme in Victoria, Australia. Controls were aged 40 years 
and above (mean age 64) and were cancer-free at the time of blood collection. This study 
was approved by the Hunter New England Human Research Ethics Committee and the Peter 
MacCallum Cancer Centre Human Research Ethics Committee.
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 Mutation screening—Cases and controls were screened for germline mutations in all 
19 exons of BRIP1 on the HiSeq 2500 System (Illumina) using the Haloplex target 
enrichment system (Agilent) as described previously.30 Paired-end sequence reads were 
aligned to the human genome (hg19 assembly) using the BWA-MEM software.31 Base 
quality score recalibration and indel realignment was performed using the GATK software. 
Single-nucleotide variants and indels were identified using the GATK Unified Genotyper 
and Variant Quality Score Recalibration.1819 Variants were annotated with information from 
Ensembl release 62. The average percentage of bases covered at a depth of ≥10× was 94.8% 
for cases and 96.1% for controls with all samples having at least 85% of bases sequenced at 
a depth of ≥10×.
All truncating variants in BRIP1 were validated by Sanger sequencing, as were any missense 
SNPs with a CADD score >10 that had not been previously reported in any databases. 
Previously reported SNPs were only validated in selected cases if the variant calling was 
unclear (quality score <150 or not identified in bidirectional reads).
 Statistical analysis
Association between each of the variants in BRIP1 and breast cancer risk was assessed in 
BCAC using logistic regression, with adjustment for study and seven principal components 
for women of European ancestry derived from genotypes of SNPs on the iCOGS array, as 
previously described.13 For the three targeted sequencing studies, we carried out burden 
analyses, which evaluated the risk associated with carrying any one of a set of likely 
deleterious variants, since the variants were too rare to be analysed individually, and this is 
directly relevant to the potential clinical application of the findings of this study. We 
considered two sets of variants: those predicted to result in a truncated protein product and 
missense substitutions with a CADD score >20. ORs and 95% CIs were calculated for each 
of the three individual studies (SEARCH, BCFR and Peter MacCallum) and combined with 
those for BCAC/iCOGS using fixed effects meta-analysis. Heterogeneity in the OR among 
studies was assessed using a standard heterogeneity χ2 test and I2 statistic.
The BCAC data set partially overlapped with SEARCH and two of the BCFR studies 
(Australian Breast Cancer Family Study (ABCFS) and Ontario Familial Breast Cancer 
Registry (OFBCR)). Since p.Arg798Ter failed the minimum coverage threshold in 
SEARCH, for simplicity we excluded the p. Arg798Ter variant, and two other missense 
variants (rs4988345 and rs28997569) that were genotyped on the iCOGS from both the 
SEARCH and BCFR sequencing data (but retained them in the BCAC data set) when 
combining the results across all data sets. This resulted in an overlap in the (non-carrier) data 
sets between the BCAC, and the SEARCH and BCFR sequencing data sets, but the resulting 
bias in the combined odds ratio would be negligible since the variants are all extremely rare. 
The most probable haplotypes for markers across the BRIP1 region were generated using 
SHAPEIT V.2.32
 Nonsense-mediated mRNA decay analysis of BRIP1 p.ArgR798Ter
To investigate whether the protein truncating mutation p. Arg798Ter triggers nonsense 
mediated decay, we treated lymphoblastoid cell lines from a heterozygous carrier and wild-
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type controls with10 mg/mL cycloheximide for 5 h. We extracted total RNA and DNA from 
treated and untreated cells with the AllPrep DNA/RNA Micro kit (Qiagen), and then 
prepared cDNA with the QuantiTect Reverse Transcription Kit (Qiagen). PCR primers for 
DNA and cDNA analysis can be provided on request. The experiment was carried out in 
triplicate.
 RESULTS
 Truncating variants
In analyses restricted to women of European ancestry, the mutant allele was observed in 23 
of 47 654 cases (0.050%) and 18 of 43 172 controls (0.04%) (OR 1.09, 95% CI 0.58 to 
2.013, p=0.79) (table 2). Consistent results were obtained when analyses were restricted to 
women with known invasive breast cancer (OR 0.95, 95% CI 0.49 to 1.83). When the 
analysis was restricted to studies without oversampling of cases with a family history and/or 
bilaterality, the results were very similar to those for the whole data set (OR 1.09, 95% CI 
0.56 to 2.09, p=0.81).
In the SEARCH, BCFR and Peter MacCallum Cancer Centre studies, we identified 34 
truncating variants in cases (0.21%) and 19 in controls (0.23%) (combined OR 0.90, 95% CI 
0.48 to 1.70, p=0.75) (table 2 and online supplementary tables S1–S3) The carrier frequency 
in controls was similar to that observed in exome sequencing data from 60 706 individuals in 
the Exome Aggregation Consortium (http://exac.broadinstitute.org/:0.21%). There was no 
evidence of heterogeneity in the OR among studies (p=0.49, I2=0.0). After elimination of the 
overlaps between BCAC and the SEARCH and BCFR data sets, the combined OR across all 
four studies for identified BRIP1 truncating variants was 0.98 (95% CI 0.62 to 1.54, p=0.93) 
(table 2).
There was weak evidence of an increased risk of oestrogen receptor (ER)-negative breast 
cancer for p.Arg798Ter carriers in BCAC (OR 2.25, 95% CI 0.93 to 5.46, p=0.07), but no 
evidence of an association with truncating variants in SEARCH (0.53, 95% CI 0.06 to 2.34, 
p=0.054; combined OR 1.71, 95% CI 0.77 to 3.80, p=0.19) (table 3). There was also weak 
evidence of an association with triple (ER/PR/HER2)-negative disease in BCAC (OR 3.62, 
95% CI 0.99 to 13.2, p=0.05) but not in SEARCH (combined OR 2.71, 95% CI 0.84 to 8.74, 
p=0.10); however, these analyses were based on only four and one triple-negative cases 
carrying the variant in BCAC and SEARCH, respectively. There was no evidence for an 
association with ER-positive disease in either data set (combined OR 0.61, 95% CI 0.33 to 
1.13, p=0.12).
 Nonsense-mediated decay
We performed Sanger sequencing on both cDNA and DNA of cycloheximide-treated and 
untreated wild-type and p.Arg798Ter lymphoblastoid cell lines (figure 2). Sequencing 
chromatograms showed that the rare, truncating allele was much less abundant than the 
wild-type allele in cDNA from untreated cells, but not in the treated cells, consistent with the 
inhibition of nonsense-mediated decay with cycloheximide.
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 Missense variants
We considered missense variants with a CADD score >20 as the most likely deleterious 
variants. There was no evidence for association between carrying one of these missense 
variants, as a set, with breast cancer risk in the combined data set (OR 1.08, 95% CI 0.95 to 
1.24, p=0.25; table 4), though there was some weak evidence of association in the Peter 
MacCallum Cancer Centre study. One variant, p.Arg173Ser, accounted for the majority of 
carriers of likely deleterious variants in the sequencing studies; it was also genotyped in 
BCAC and showed no evidence of association (combined OR 1.07, 95% CI 0.93 to 1.23, 
p=0.35). None of the other missense variants genotyped in BCAC showed evidence for 
association (table 1).
 Distribution of p.Arg798Ter by population
Among European populations, there was substantial variation in the frequency of the 
p.Arg798Ter allele by country (p<0.0001); the carrier frequency was approximately 0.1% in 
the UK, Ireland and Australia, but virtually absent elsewhere in Europe. Also, 41 of the 42 
carriers shared a common haplotype of 21 markers across 150 kb (see online supplementary 
figure s1 and supplementary table S4). In addition, we observed two occurrences among 12 
893 women of Asian ancestry, both from a Malaysian study (MYBRCA) and both carrying 
the common haplotype in Europeans, and two occurrences among 2048 African-American 
women, one of which carried the founder European haplotype. These results suggest that the 
variant has arisen multiple times but that the majority of the carriers of p. Arg798Ter in 
Europeans have a common ancestral origin.
 DISCUSSION
BRIP1 is included on many cancer gene sequencing panels and has been generally regarded 
as a ‘moderate-risk’ breast cancer susceptibility gene, together with other genes, including 
ATM, CHEK2 and PALB2.2 The evidence that deleterious mutations in these latter three 
genes confer an increased breast cancer risk is unequivocal, supported by large case–control, 
kin–cohort and segregation studies.2233–37 In the case of BRIP1, however, it is notable that 
no large systematic studies have been published since the original study by Seal et al6 (see 
online supplementary table S1), although clear evidence of an association between 
truncating mutations and ovarian cancer risk has emerged.3839 We sought to evaluate the 
evidence that protein truncating mutations in BRIP1 are associated with breast cancer, taking 
advantage of the large body of data generated as part of the iCOGS genotyping array. This 
allowed us to genotype one such variant, p.Arg798Ter, shown to be relatively frequent in 
previous studies, in >48 000 cases and 43 000 controls of European origin. In addition, we 
sequenced the coding region of BRIP1 in >16 000 cases and 8000 controls, predominantly 
of European origin, from three studies. We found no evidence of an association with breast 
cancer risk either for p. Arg798Ter or for carrying any truncating variant in the gene. The 
upper 95% confidence limit (1.54) excludes a twofold risk of breast cancer, often taken as a 
lower threshold for a moderate-risk allele.2
We found weak evidence of an association between p. Arg798Ter and ER-negative disease 
and triple-negative disease in BCAC, but not for truncating variants in the combined 
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analysis. A recent study found eight BRIP1 truncating variants in 1853 triple-negative breast 
cancer cases, slightly higher than the frequency observed in our sequence analysis.40 
Assuming that there is association for triple-negative breast cancer, a sample size of ~1400 
triple-negative cases, that is approximately threefold larger than the current data set, would 
be required to exclude an OR of 3 (upper 95% CI), assuming a large control set. Thus, while 
an association of this magnitude may exist for triple-negative disease, this should be 
resolvable by larger studies.
It remains possible that some subset variants in BRIP1 do confer more substantial risks of 
breast cancer. p.Arg798Ter is a classic protein truncating mutation, which we showed 
undergoes nonsense-mediated decay. Rare homozygotes, with complete loss of the BRIP1 
protein, are associated with Fanconi Anaemia.4 Although the results from the sequence 
analyses found no other truncating variants of comparable frequency to pArg798Ter, 
additional founder mutations might exist at similar or greater frequency in other European or 
non-European populations. We also found no evidence of association for missense variants, 
defined as potentially deleterious by CADD score; again the upper 95% confidence limit in 
this analysis excludes a twofold risk, though it remains possible that individual missense 
variants might confer a more substantial risk, as occurs in ATM.41–43
It also remains possible that truncating (or missense) variants are associated with a smaller 
(less than twofold) risk of breast cancer (perhaps with a higher relative risk for certain 
disease subtypes). However, in this case even larger studies would be required to establish 
the association and to provide reliable risk estimates. Moreover, this would place such 
variants in the same category as common risk SNPs and other modest risk variants, such as 
CHEK2 p.Ile157Thr and BRCA2 p.Lys3326Ter. If this were the case, the clinical 
implications would be quite different from those of established susceptibility genes since the 
risks conferred by the variant would only be substantial if combined with other risk factors.
These results highlight the importance of very large systematic studies to estimate disease 
risks associated with genetic variants. We conclude that there is no clear evidence for an 
association between protein truncating variants in BRIP1 and breast cancer risk. While 
BRIP1 screening might have utility for ovarian cancer risk prediction, in combination with 
other risk factors,39 such variants should not be used for breast cancer risk prediction.
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Figure 1. 
Cluster plot for genotype intensities for rs137852986 on the iCOGS array. Normalised 
intensities for the variant and wild-type allele for each individual are given by the X and Y 
coordinates, respectively. Individuals called as p.Arg798Ter carriers are indicated by green 
dots and non-carriers by blue dots. The red dot indicates a positive control individual known 
to carry the variant from prior sequencing. BCAC, Breast Cancer Association Consortium; 
NC, no call.
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Figure 2. 
Sequencing of cDNA from a cycloheximide-treated and untreated lymphoblastoid cell line 
from a BRIP1 p.Arg798Ter carrier. Forward sequence of (A) cDNA from cycloheximide-
treated lymphoblastoid cell line, (B) cDNA from the untreated lymphoblastoid cell line and 
(C) DNA sequence from the same cell line.
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Table 2
Association between protein truncating variants in BRIP1 and breast cancer risk
Study Case carriers/total (%) Control carriers/total (%) OR (95% CI) p Value
BCAC 23/47,654 (0.05%) 18/43,172 (0.04%) 1.09 (0.58 to 2.03) 0.79
SEARCH 24/13,213 (0.18%) 13/5242 (0.25%) 0.73 (0.36 to 1.57) 0.36
BCFR 4/1313 (0.30%) 2/1123 (0.27%) 1.71 (0.24 to 19.0) 0.69
PeterMac 6/1853 (0.38%) 4/2001 (0.20%) 1.62 (0.38 to 7.82) 0.45
Combined 0.98 (0.62 to 1.54) 0.93
BCAC, Breast Cancer Association Consortium; BCFR, Breast Cancer Family Registry.
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Table 4
Association between missense variants in BRIP1 with Combined Annotation-Dependent Depletion score >20 
and breast cancer risk
Study Case carriers/total (%) Control carriers/total (%) OR (95% CI) p Value
BCAC 429/47,666 (0.90%) 370/43,176 (0.86%) 1.06 (0.92 to 1.22) 0.43
SEARCH 276/13,213 (2.1%) 107/5242 (2.0%) 1.06 (0.85 to 1.32) 0.66
BCFR 0/1313 (0%) 1/1123 (0.09%) –
PeterMac 40/1853 (2.2%) 28/2001 (1.4%) 1.68 (1.02 to 2.82) 0.03
Combined 1.08 (0.95 to 1.24) 0.25
BCAC, Breast Cancer Association Consortium; BCFR, Breast Cancer Family Registry.
J Med Genet. Author manuscript; available in PMC 2016 November 01.
